Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 47% year-over-year to $7,900,000, exceeding guidance of $7,800,000, driven by balanced growth in the Vinia business [6][22] - Gross profit rose by 53% to $4,600,000, representing a gross margin of 58.5%, up from 56.2% in the same quarter last year [22][23] - Net losses for Q1 2025 totaled $2,300,000, or $0.13 per share, compared to a net loss of $6,600,000, or $0.48 per share in the same quarter last year [23][24] Business Line Data and Key Metrics Changes - The Direct to Consumer Health and Wellness Products Division, led by Vinia, accounted for the majority of revenue, with total active subscribers exceeding 50,000 in the USA [6][10] - The Amazon channel represented 20% of the business, showing improvements in customer conversion and repeat purchase rates [6] - The CDMO services division has signed multiple customers, including a partnership with Tate and Lyle for developing next-generation plant-based sweeteners [16][17] Market Data and Key Metrics Changes - The company reported a significant increase in gross margins, attributed to scaling operations and cost efficiencies [7][8] - The rollout of new products, including superfood tea and coffee, is expected to capture additional market segments [10][12] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven at $11,000,000 to $12,000,000 in quarterly revenue by the second half of 2025 [18] - Strategic focus includes expanding the direct-to-consumer portfolio, investing in R&D for process improvements, and building AI-powered tools for CDMO services [19] - The company plans to launch new products targeting younger consumers and expand into the hydration and beauty markets [62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute and deliver on the company's mission to democratize life-changing compounds [25] - The company is optimistic about the growth potential in the pharmaceutical sector, driven by increasing interest in non-GMO and plant-based compounds [72][74] - Management highlighted the importance of regulatory flexibility and the potential for significant revenue opportunities in the pharmaceutical market [73] Other Important Information - Cash and cash equivalents as of March 31, 2025, totaled $3,400,000, an increase from $2,400,000 at the end of 2024 [24] - The company raised $3,900,000 in debt financing during the quarter, primarily from existing investors [24] Q&A Session Summary Question: Can you provide details on the Phase two portion of the CDMO contract? - The transition to Phase two involves moving from solid media to liquid media for cell conditioning, expected to take six to nine months [28][30] Question: How long will it take to narrow down targets with Tate and Lyle? - Significant work is underway, with a comprehensive update expected before the end of the year [32] Question: Should we anticipate continued gross margin expansion? - Management expects continued improvements in gross margins alongside revenue growth [34] Question: How many products contributed to revenue in Q1? - The majority of revenue came from three product lines, with expectations to increase to four by Q2 [39][40] Question: Will marketing costs drop due to increased ad inventory? - The company is focused on reducing marketing costs as a percentage of revenue while exploring new channels [42][46] Question: Does the second quarter guidance include CDMO contributions? - Yes, it includes revenue recognition from existing projects and potential new catalysts [47] Question: How many CDMO programs can be run concurrently? - The company can handle five to seven projects at one time in the initial stages [51] Question: What is the timeline for the olive cell product? - The product is expected to launch in 2026, with a faster ramp-up anticipated due to complementary marketing strategies [84]

Grow with Ginkgo Q1 2025 Update & Business Review May 6, 2025 Property of Ginkgo Bioworks — 1 Q1 2025 UPDATE & BUSINESS REVIEW Disclaimer FORWARD-LOOKING STATEMENTS This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the tim ...

Ginkgo Bioworks (DNA) Q1 2025 Earnings Call May 06, 2025 05:30 PM ET Speaker0 Communications and ownership. It's my third year here at Ginkgo. I've spent much of that time working behind the scenes with our investor relations team on these earnings calls, but I'm thrilled to be joining you for the first time live on air. I'm joined by Jason Kelly, our cofounder and CEO, and Mark Demetriuk, our CFO. Thanks as always for joining us. We're looking forward to updating you on our progress. As a reminder, during ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Jason Kelly - Founder, CEO & Director Conference Call Participants Jason Lai - Morgan Stanley Evie Kslosky - Goldman Mark Massaro - BTIG Brendan Smith - TD Cowen Matt Larew - William Blair & Company Joseph Fridman Good evening. I'm Joseph Fridman, Director of Comm ...